Vaxcyte, Inc. is a clinical-stage biotechnology company. The company is specializes in engineering high-fidelity vaccines to prevent or treat serious bacterial infectious diseases. Vaxcyte leverages its proprietary XpressCF cell-free protein synthesis platform to build broad-spectrum conjugate and novel protein vaccines. The company's flagship candidate is VAX-31, a 31-valent pneumococcal conjugate vaccine designed to protect against invasive pneumococcal disease and pneumonia.